Tags

Type your tag names separated by a space and hit enter

Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
Acta Ophthalmol Scand. 2007 Feb; 85(1):80-3.AO

Abstract

PURPOSE

To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol-dorzolamide combination in patients with primary open-angle glaucoma (POAG) or ocular hypertension during 6 months of treatment.

METHODS

A sample of 65 patients with a diagnosis of POAG or ocular hypertension were randomized to receive either bimatoprost 0.03% once daily or timolol-dorzolamide combination twice daily. Study visits occurred at baseline and after 2 weeks and 1, 3 and 6 months of therapy. Intraocular pressure (IOP) measurements were performed at 12.00 hours at all study visits and also at 08.00 hours and 16.00 hours at baseline and 6-month visits. At each visit, local and systemic side-effects that occurred during the treatment period were recorded. Student's t-test was used to compare the differences between IOP values.

RESULTS

Differences in IOP between the bimatoprost and timolol-dorzolamide groups were statistically insignificant at all study visits (p > 0.05). In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment. The difference was not statistically significant (p = 0.48).

CONCLUSIONS

The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up. Both bimatoprost and the timolol-dorzolamide combination were well tolerated. Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.

Authors+Show Affiliations

Department of Ophthalmology, School of Medicine, University of Afyon Kocatepe, Afyon, Turkey.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17244215

Citation

Ozturk, Faruk, et al. "Comparison of the Ocular Hypotensive Effects of Bimatoprost and Timolol-dorzolamide Combination in Patients With Elevated Intraocular Pressure: a 6-month Study." Acta Ophthalmologica Scandinavica, vol. 85, no. 1, 2007, pp. 80-3.
Ozturk F, Ermis SS, Inan UU. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study. Acta Ophthalmol Scand. 2007;85(1):80-3.
Ozturk, F., Ermis, S. S., & Inan, U. U. (2007). Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study. Acta Ophthalmologica Scandinavica, 85(1), 80-3.
Ozturk F, Ermis SS, Inan UU. Comparison of the Ocular Hypotensive Effects of Bimatoprost and Timolol-dorzolamide Combination in Patients With Elevated Intraocular Pressure: a 6-month Study. Acta Ophthalmol Scand. 2007;85(1):80-3. PubMed PMID: 17244215.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study. AU - Ozturk,Faruk, AU - Ermis,Sitki Samet, AU - Inan,Umit Ubeyt, PY - 2007/1/25/pubmed PY - 2007/3/16/medline PY - 2007/1/25/entrez SP - 80 EP - 3 JF - Acta ophthalmologica Scandinavica JO - Acta Ophthalmol Scand VL - 85 IS - 1 N2 - PURPOSE: To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol-dorzolamide combination in patients with primary open-angle glaucoma (POAG) or ocular hypertension during 6 months of treatment. METHODS: A sample of 65 patients with a diagnosis of POAG or ocular hypertension were randomized to receive either bimatoprost 0.03% once daily or timolol-dorzolamide combination twice daily. Study visits occurred at baseline and after 2 weeks and 1, 3 and 6 months of therapy. Intraocular pressure (IOP) measurements were performed at 12.00 hours at all study visits and also at 08.00 hours and 16.00 hours at baseline and 6-month visits. At each visit, local and systemic side-effects that occurred during the treatment period were recorded. Student's t-test was used to compare the differences between IOP values. RESULTS: Differences in IOP between the bimatoprost and timolol-dorzolamide groups were statistically insignificant at all study visits (p > 0.05). In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment. The difference was not statistically significant (p = 0.48). CONCLUSIONS: The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up. Both bimatoprost and the timolol-dorzolamide combination were well tolerated. Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension. SN - 1395-3907 UR - https://www.unboundmedicine.com/medline/citation/17244215/Comparison_of_the_ocular_hypotensive_effects_of_bimatoprost_and_timolol_dorzolamide_combination_in_patients_with_elevated_intraocular_pressure:_a_6_month_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1395-3907&date=2007&volume=85&issue=1&spage=80 DB - PRIME DP - Unbound Medicine ER -